Needham upgraded Gilead (GILD) to Buy from Hold with a $133 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead announces CHMP opinion recommending lenacapavir
- Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications
- Gilead Sciences Advances HIV Prevention with New Clinical Study
- Positive Outlook for Gilead Sciences Amid Strong HIV and Veklury Performance
- Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update